Idenix Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Daniel Da Costa

David Dukhan

Jean-Laurent Paparin

Houcine Rahali

Cyril B Dousson

Izzat Tiedje Raheem

Dominique Surleraux

Francois-Rene Alexandre

Christophe Parsy

Claire Pierra

Thierry Convard

Guillaume Brandt

Michel Derock

John D Schreier

Timothy John Hartingh

Aurélien Salanson

Christophe Claude Parsy

Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. 

Antiviral aryl-amide phosphodiamide compounds

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral aliphatic ester prodrugs of tenofovir

Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Antiviral prodrugs of tenofovir

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Growing community of inventors

Montarnaud, France

Daniel Da Costa